Form 4: Polly Murphy Acquires Atea Pharmaceuticals Stock

Polly Murphy, a Director at Atea Pharmaceuticals, Inc., reported the acquisition of 6,100 shares of common stock.

Summary

• Polly A. Murphy, a Director at Atea Pharmaceuticals, Inc. (AVIR), acquired 6,100 shares of common stock on May 18, 2025.
• The purchase was made at a weighted average price of $4.1715 per share, with individual transactions ranging from $4.14 to $4.19.
• Following this transaction, Ms. Murphy beneficially owns 92,145 shares of common stock directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents an insider increasing their stake, but it does not provide new operational or financial performance data.

Positives

• Director Polly A. Murphy has increased her direct beneficial ownership of Atea Pharmaceuticals common stock.
• The acquisition of 6,100 shares indicates a continued investment by a key insider in the company.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that insider stock acquisitions, particularly by directors, can be interpreted as a positive signal of confidence in the company's future prospects within the biotechnology sector.

Stakeholder Impact

• Shareholders may view this acquisition positively as a sign of insider confidence in the company's value.

Key Dates

Keywords

Atea Pharmaceuticals, AVIR, Form 4, Insider Trading, Stock Acquisition, Beneficial Ownership, Director Transaction